Bohui Innovation(300318)

Search documents
博晖创新(300318) - 董事会决议公告
2025-04-25 10:17
证券代码:300318 证券简称:博晖创新 公告编号:临 2025-007 北京博晖创新生物技术集团股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 第八届董事会第十次会议于 2025 年 4 月 25 日在公司会议室召开,会议通知于 2025 年 4 月 15 日以专人送达、邮件通知或电话通知的方式送达各位董事,会议由公司董 事长沈治卫先生主持,会议采取现场和通讯表决相结合方式进行,本次会议应出席 董事 7 人,实际出席董事 7 人,监事人员及高级管理人员列席了会议。本次会议的 召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议通过了以下议案: 1、审议通过《2024 年度董事会工作报告》 《2024 年度董事会工作报告》详见巨潮资讯网(www.cninfo.com.cn)。 表决结果:7 票同意,0 票反对,0 票弃权。同意票数占总票数的 100%。 本议案尚需提交公司股东大会审 ...
博晖创新(300318) - 2024年度利润分配预案的公告
2025-04-25 10:16
证券代码:300318 证券简称:博晖创新 公告编号:临 2025-010 北京博晖创新生物技术集团股份有限公司 2024 年度利润分配预案的公告 2、公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第 9.4 条相关规定的可能被实施其他风险警示情形。 一、审议程序 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 于 2025 年 4 月 23 日召开第八届董事会第二次独立董事专门会议;于 2025 年 4 月 25 日召开第八届董事会第十次会议和第八届监事会第九次会议,审议通过了 《2024 年度利润分配预案》。 1、独立董事专门会议意见 独立董事认为:董事会提出的利润分配预案从公司的实际情况出发,符合公 司未来经营发展的需要,不存在损害投资者利益的情形,同意将该方案提交董事 会审议。 2、董事会意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 特别提示: 1、公司 2024 年度拟不派发现金红利,不送红股,不以资本公积金转增股 本。 董事会认为,公司 2024 年度利润分配预案综合考虑了公司 2025 年的经营计 划和 ...
博晖创新(300318) - 关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜的公告
2025-04-25 10:14
证券代码:300318 证券简称:博晖创新 公告编号:临 2025-011 北京博晖创新生物技术集团股份有限公司 关于提请股东大会授权董事会 办理以简易程序向特定对象发行股票相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 于 2025 年 4 月 25 日召开第八届董事会第十次会议,审议通过《关于提请股东大 会授权董事会办理以简易程序向特定对象发行股票相关事宜的议案》。 根据《上市公司证券发行注册管理办法》(以下简称"《注册管理办法》")、 《深圳证券交易所上市公司证券发行上市审核规则》(以下简称"《审核规则》")、 《深圳证券交易所上市公司证券发行与承销业务实施细则》(以下简称"《实施 细则》")及《公司章程》等相关规定,公司董事会提请股东大会授权董事会向 特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的 股票,授权期限为 2024 年度股东大会通过之日起至 2025 年度股东大会召开之日 止。上述事项尚需提交 2024 年度股东大会审议。具体 ...
博晖创新:2024年报净利润0.09亿 同比增长136%
Tong Hua Shun Cai Bao· 2025-04-25 10:13
Financial Performance - The company reported a basic earnings per share of 0.0113 yuan for 2024, a significant increase of 137.05% compared to a loss of 0.0305 yuan in 2023 [1] - The net profit for 2024 was 0.09 billion yuan, recovering from a loss of 0.25 billion yuan in 2023, marking a 136% improvement [1] - Operating revenue decreased to 8.52 billion yuan in 2024, down 18.47% from 10.45 billion yuan in 2023 [1] - The return on equity improved to 0.67% in 2024 from -1.80% in 2023, reflecting a recovery in profitability [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 49,809.64 million shares, accounting for 62.37% of the circulating shares, with a decrease of 246,000 shares compared to the previous period [1] - Du Jiangtao remains the largest shareholder with 31,881.14 million shares, representing 39.92% of the total share capital, unchanged from the previous report [2] - Yang Qi reduced his holdings by 210.44 million shares, while Lu Yang increased his holdings by 473 million shares [2] Dividend Policy - The company has decided not to distribute dividends or increase capital through bonus shares [3]
博晖创新(300318) - 2024 Q4 - 年度财报
2025-04-25 10:00
Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 0 RMB per 10 shares and no bonus shares, based on a total of 816,900,495 shares[3]. - The company's operating revenue for 2024 was ¥851,694,578.15, a decrease of 18.53% compared to ¥1,045,429,099.92 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥9,245,978.84, representing a significant increase of 137.09% from a loss of ¥24,929,391.08 in 2023[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,329,787.16, up 144.58% from a loss of ¥27,657,660.92 in 2023[20]. - The net cash flow from operating activities for 2024 was -¥38,691,051.23, a decline of 128.24% compared to ¥137,017,197.71 in 2023[20]. - The total assets at the end of 2024 were ¥4,125,558,100.42, an increase of 5.08% from ¥3,926,015,273.52 at the end of 2023[20]. - The net assets attributable to shareholders at the end of 2024 were ¥1,378,686,990.40, a slight increase of 0.67% from ¥1,369,538,542.38 at the end of 2023[20]. - The company reported a total revenue of ¥576.92 million from biological products, with a gross margin of 42.46%, down 20.50% year-over-year[88]. - The revenue from the biological products segment was ¥576,922,488.10, accounting for 67.74% of total revenue, down 20.50% from ¥725,659,469.73 in the previous year[84]. Market Overview - The company operates in the in-vitro diagnostic (IVD) industry, which is crucial for clinical diagnosis and has a global market size of $81 billion in 2024, down 30% year-on-year[32]. - The Chinese in vitro diagnostic market is expected to reach nearly 120 billion RMB in 2024, remaining stable compared to 2023, with local brand products accounting for approximately 50%[34]. - The in vitro diagnostic market in China is projected to grow at a compound annual growth rate (CAGR) of 5-8% over the next five years, potentially reaching around 165 billion RMB by 2029[34]. - The blood products market in China is expected to reach 60 billion RMB by 2024, with a projected growth to 78 billion RMB by 2027, reflecting a CAGR of 11.6% from 2022 to 2027[41]. - The global blood products market is anticipated to exceed 93.1 billion USD by 2030, maintaining a CAGR of approximately 10%[40]. Product Development and Innovation - The company is focused on technological innovation in the life sciences sector, particularly in the fields of testing instruments and biological products[30]. - The company is developing a quantum dot fluorescence immunoassay analyzer, which will be compatible with various diagnostic kits, scheduled for launch in May 2026[58]. - The company is also set to release multiple allergen-specific IgE antibody testing kits by July 2027, targeting various environmental and food allergens[58]. - The company reported a significant increase in R&D investment, focusing on innovative diagnostic technologies and expanding its product portfolio[59]. - The company is actively pursuing regulatory approvals to support its growth strategy in the biopharmaceutical market[69]. Regulatory Compliance and Governance - The financial report has been confirmed as true, accurate, and complete by the company's management, including the CEO and accounting heads[3]. - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and maintaining a clear governance structure[148]. - The company has established a robust investor relations management system, fostering good interactions with investors[156]. - The company has a complete and independent financial accounting system, ensuring financial decisions are made independently[162]. - The company respects the rights of stakeholders, including banks, employees, suppliers, and customers, promoting sustainable development[155]. Strategic Initiatives - The company aims to enhance its core competitive advantages and improve operational efficiency through product research and innovation, as well as marketing capability development[125]. - The company plans to focus on the medical health industry, emphasizing both internal growth and external expansion strategies[125]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential deals[7]. - The company is committed to maintaining high-quality standards in its diagnostic products, ensuring compliance with regulatory requirements[59]. - The company aims to optimize its supply chain and diversify sales channels in response to the significant price reductions in HPV products due to centralized procurement initiatives starting in 2024[130]. Human Resources and Talent Development - The total number of employees at the end of the reporting period is 2,179, with 252 in the parent company and 1,927 in major subsidiaries[195]. - The employee composition includes 1,117 technical personnel, 487 production personnel, and 218 sales personnel, indicating a strong focus on technical expertise[195]. - The company emphasizes a competitive and performance-oriented compensation policy to attract and retain high-performing employees[197]. - The training program includes a three-tier talent pool covering core business units, ensuring a strong talent pipeline for sustainable development[198]. - The company has 16 employees with a doctoral degree and 73 with a master's degree, reflecting a highly educated workforce[195].
【医药】对美征收关税带来血制品行业重大机遇——对美商品加征关税政策点评(王明瑞/张杰)
光大证券研究· 2025-04-07 08:46
Core Viewpoint - The recent imposition of a 34% tariff on U.S. imports by China is expected to benefit domestic blood product companies, as it may lead to a price increase for imported human albumin, thereby enhancing the market share of domestic products [3][4]. Group 1: Market Impact - The demand for blood products is relatively inelastic, and the tariff is unlikely to significantly affect overall demand due to its essential nature [4]. - China imports over 60% of its human albumin products, with the U.S. being a major supplier, exporting $54.6 billion in blood products in 2024 [4]. - The price of imported human albumin is expected to rise, reducing its competitive advantage over domestic products, which may lead to an increase in market share for local companies [5]. Group 2: Pricing Dynamics - As of April 6, 2025, domestic human albumin prices are slightly higher than imported ones, but the tariff may eliminate the price advantage of imports [5]. - For example, the price range for imported human albumin (10g specification) is between 345-438 RMB, while domestic products range from 359-580 RMB [5]. Group 3: Supply Chain and Industry Structure - The blood product industry is characterized by a limited number of manufacturers, creating an oligopoly with companies like Tian Tan Bio, Shanghai Raist, and Hualan Biological [6]. - The industry is less affected by geopolitical risks due to its self-sufficient supply chain and the nature of its products [6][7]. - The ongoing trade tensions may enhance the internal circulation advantages of the blood product industry, supporting its long-term growth prospects [7].
博晖创新(300318) - 关于获得政府补助的公告
2025-04-03 08:12
关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 于 2025 年 4 月 2 日收到政府补助资金 290.00 万元,占公司 2023 年度经审计归 属于上市公司股东的净利润的 11.63%。具体情况如下: | 获得补助 | 收到补助 | | 补助 | 补助金额 | 是否与公司 日常经营活 | 是否已经 实际收到 | 是否具有 | | --- | --- | --- | --- | --- | --- | --- | --- | | 的主体 | 的时间 | | 形式 | (万元) | | | 可持续性 | | | | | | | 动相关 | 相关款项 | | | 博晖创新 | 2025 4 | 年 | 现金 | 290.00 | 是 | 是 | 否 | | | 月 2 | 日 | | | | | | 二、补助的类型及其对上市公司的影响 证券代码:300318 证券简称:博晖创新 公告编号:临 2025-006 北京博晖创新生物技术集团股份有限 ...
博晖创新收盘上涨4.36%,最新市净率3.37,总市值46.89亿元
Sou Hu Cai Jing· 2025-04-01 09:34
Group 1 - The core viewpoint of the news is that Beijing Bohui Innovation Biotechnology Group Co., Ltd. has shown a mixed performance in its latest financial results, with a significant decline in revenue but an increase in net profit [1] - As of September 30, 2024, the number of shareholders for Bohui Innovation has increased to 33,750, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business includes inspection and testing services as well as biological products, with key products such as HPV testing products, trace element testing products, and blood products [1] Group 2 - In the latest financial report for Q3 2024, the company reported an operating income of 646 million yuan, a year-on-year decrease of 19.85%, while net profit reached 23.72 million yuan, reflecting a year-on-year increase of 67.77% [1] - The company's gross profit margin stands at 50.65%, indicating a strong profitability despite the decline in revenue [1] - The company's price-to-earnings (PE) ratio is significantly high at -305.50, compared to the industry average of 46.46, suggesting potential overvaluation or market concerns [2]
博晖创新收盘下跌1.92%,最新市净率3.30,总市值45.91亿元
Sou Hu Cai Jing· 2025-03-28 09:43
序号股票简称PE(TTM)PE(静)市净率总市值(元)3博晖创新-299.11-184.163.3045.91亿行业平均 45.2249.254.85107.95亿行业中值32.5731.042.4948.28亿1硕世生物-1928.41-1928.411.2139.84亿2诺唯 赞-570.10-570.102.4696.93亿4康泰医学-292.1334.272.9856.81亿5华大基因-217.12237.502.25220.63亿6奥 精医疗-119.63-119.631.5221.67亿7睿昂基因-82.87-82.871.2911.99亿8华大智造-55.62-55.624.17333.25亿9 中红医疗-54.23-36.890.8648.28亿10热景生物-49.79-49.792.7489.25亿11天智航-46.17-46.174.8256.85亿 来源:金融界 北京博晖创新生物技术集团股份有限公司的主营业务为检验检测业务及生物制品业务。公司主要产品有 HPV检测产品、微量元素检测产品、质谱相关检测产品、其他耗材及服务、人血白蛋白、静注人免疫球 蛋白、其他血液制品。 最新一期业绩显示,2 ...
博晖创新: 关于控股子公司向控股孙公司提供担保的公告
Zheng Quan Zhi Xing· 2025-03-25 10:08
一、担保事项概述 近日,公司控股孙公司博晖生物制药(云南)有限公司(以下简称"云南博 晖")作为借款人、公司作为共同借款人与中国工商银行股份有限公司曲靖分行 (以下简称"工商银行")共同签署《固定资产借款合同》(编号:2025年(城 办)字00003号),向工商银行申请借款500,000,000元(大写:人民币伍亿元整), 借款期限7年。 公司控股子公司博晖生物制药(河北)有限公司(以下简称"河北博晖") 将其持有的云南博晖100%股权质押给工商银行,为本次借款事项提供质押担保; 云南博晖抵押其土地使用权、地上在建工程及机器设备,为本次借款事项提供抵 押担保;公司控股股东、实际控制人及其配偶以其个人信用,为本次借款事项提 供保证担保;公司控股股东、实际控制人及其配偶以其持有的内蒙古君正能源化 工集团股份有限公司股票,为本次借款事项提供质押担保;公司关联方乌海市君 正科技产业集团有限责任公司( 博晖创新: 关于控股子公司向控股孙公司提供担保 的公告 证券代码:300318 证券简称:博晖创新 公告编号:临 2025-005 北京博晖创新生物技术集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确 ...